Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 4;11:685. doi: 10.1038/s41467-020-14502-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a LMP1 fails to induce JNK after the knockout of IKK2 in MEFs. LMP1 activity was induced by antibody crosslinking and JNK activation was monitored by immunoblotting. b Pharmacological inhibition of IKK activity interferes with JNK activation by LMP1. NGFR-LMP1 was induced in the presence of solvent (DMSO) or 5 μM of the IKK inhibitor VIII (ACHP). c, d IKK2 has a unique role in LMP1 signaling as compared to the TNFα and IL-1 pathways. Wildtype and IKK2^−/−MEFs were stimulated with 20 ng/ml TNFα (c) or 10 ng/ml IL-1 (d) for the indicated times. e IKK1 is dispensable for JNK activation by LMP1. IKK1 was targeted by CRISPR/Cas9 in wildtype MEF:NGFR-LMP1wt and IKK2^−/−MEF:NGFR-LMP1wt cells. LMP1 activity was induced in non-targeted, IKK1^crKOMEF:NGFR-LMP1wt (clone 69) and IKK1^crKOIKK2^−/−MEF:NGFR-LMP1wt (clone 8) cells. Activation of JNK and canonical NF-κB was monitored. f The knockout of NEMO causes a defect in JNK activation by LMP1. NEMO was inactivated in wtMEF:NGFR-LMP1wt cells by CRISPR/Cas9 technology. NGFR-LMP1 activity was induced in non-targeted cells and the NEMO^crKO clones 2, 7, and 19. JNK and canonical NF-κB were analysed. CRISPR/Cas9 knockouts were verified by immunoblotting (this Figure) and sequencing (see Supplementary Table 2). a–f The data are representative of at least two independent experiments. For immunoblot quantification and statistics see Supplementary Table 3.